Educational information, not financial advice or a personal recommendation. Not regulated by the FCA. Do your own research. Capital at risk.
Sterling AlmanacExploreStart hereFind your fitGlossaryCompareMy ListMy PieEarnings calendarSupport

Intellia Therapeutics, Inc. (NTLA)

Healthcare Out of favour

Intellia Therapeutics is a biotech firm working on gene-editing technology to potentially cure serious diseases by fixing DNA directly inside the body.

$10.68

Is Intellia Therapeutics, Inc. a good stock for a UK beginner?

The honest version: Intellia Therapeutics is a biotech firm working on gene-editing technology to potentially cure serious diseases by fixing DNA directly inside the body.

No rating · no target price · nothing for sale here
Price-57.5%
Priced in USD - as a UK investor your £ return also moves with the pound-to-dollar exchange rate, on top of the share price itself.
52-week range-16% past year
$10.68
Low $7.95High $28.25
Where today's price sits versus its past year - context, not a signal.
If you had put $1,000 into Intellia Therapeutics, Inc.
$425-58%

Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.

Market cap: The company's total value on the stock market - share price times the number of shares. Big = 'large-cap', small = 'small-cap'.
$1.49B
Avg volume: How many shares change hands on a typical day. Higher means it's easy to buy or exit without moving the price.
5.67M
Day range: The lowest and highest price the shares traded at during the latest day.
$10.60 – $11.19
52-week range: The lowest and highest the shares have traded over the past year - a sense of how wide the swings have been.
$7.95 – $28.25
Dividend yield: The yearly dividend as a percentage of the share price - roughly the income you'd earn from dividends alone.
0.0%
Beta: How bumpy the share price is versus the whole market. Above 1 swings more than the market; below 1 is calmer. It's about the ride, not whether it goes up or down.
1.77
How bumpy is it?Beta: How bumpy the share price is versus the whole market. Above 1 swings more than the market; below 1 is calmer. It's about the ride, not whether it goes up or down. 1.77
Calm
Wild
Bumpier than the market

Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.

Why has it been moving?▼ -2% past week · ▼ -16% past year

Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.

The bull case

Commercialisation of a successful gene therapy

The bear case

Inability to bring a product to market

What does Intellia Therapeutics, Inc. do?

Intellia is essentially a scientific research powerhouse focused on CRISPR technology, which acts like a pair of molecular scissors to edit faulty genes. Because they are still in the testing phase for their treatments, they aren't yet making a profit from sales, meaning they rely on cash reserves to fund their expensive lab work. Everything hinges on their progress in clinical trials, since future success depends entirely on proving these complex treatments are safe and effective for patients.

VQGMI
Factor profile

On our factor screen it looks strongest on value and quality, and weakest on growth.

Value: How cheap the stock looks versus profits, sales and assets (higher = cheaper). 65Quality: How profitable and financially healthy the company is (higher = stronger). 26Growth: How fast revenue and earnings are growing (higher = faster). 4Momentum: How the share price has been trending recently (higher = stronger recent run). 12Income: The dividend income on offer and how sustainable it looks (higher = more/steadier). 16
Quick checks
What's strong
  • Pioneering technology with the potential to treat previously incurable diseases
  • Strong intellectual property portfolio in the CRISPR field
  • High interest from the scientific and medical community
What to watch
  • Quality screens low (26/100)
  • Growth screens low (4/100)
  • Momentum screens low (12/100)
  • Income screens low (16/100)
  • Clinical trial failures could halt development entirely

What do Intellia Therapeutics, Inc.'s numbers mean?

P/S
27.6
This shows how much investors are paying for every pound of revenue, and a high number suggests people are betting heavily on future growth rather than current sales.
P/B
2.5
This compares the company's market value to the value of its physical assets, showing how much of the price is based on future potential rather than what they own today.
Beta
1.8
A beta above 1 means the share price tends to be much more jumpy and volatile than the wider stock market.
Return on equity
-56.3%
This negative figure reflects that the company is currently spending more money on research and development than it is generating in profit.

How much money does Intellia Therapeutics, Inc. make?

Revenue and profit by quarter, and how much of each sale turns into profit.

RevenueNet income
$0$5.75M$11.51M$17.26M$23.02MQ1 25Q2 25Q3 25Q4 25Q1 26
Gross margin
0.0%
Net margin
0.0%
Return on equity
-56.3%

Does Intellia Therapeutics, Inc. pay a dividend?

No - Intellia Therapeutics, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.

More in Healthcare

Eli LillyWest Pharmaceutical Services, Inc.Incyte CorporationThe Cigna GroupZimmer Biomet Holdings, Inc.Moderna, Inc.Gilead Sciences, Inc.Regeneron Pharmaceuticals, Inc.

What are the scenarios for Intellia Therapeutics, Inc.?

An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.

$29$11$6today · $11▲ Bull · $13• Base · $11▼ Bear · $8in 1 yearILLUSTRATIVE · NOT A PREDICTION OR PRICE TARGET
Bull
+15% to +25%Positive data releases from ongoing clinical trials
Base
-5% to +5%Steady progress without major news
Bear
-15% to -30%Delays or safety concerns in the testing pipeline

What are the pros and cons of Intellia Therapeutics, Inc.?

3bull points
6bear points

How many points the write-up makes each way — a balance check, not a score or verdict.

The bull case3
  • Pioneering technology with the potential to treat previously incurable diseases
  • Strong intellectual property portfolio in the CRISPR field
  • High interest from the scientific and medical community
The catch3
  • No current revenue or profit from product sales
  • High cash burn rate to support research
  • Highly volatile share price compared to the broader market
Key risks3
  • Clinical trial failures could halt development entirely
  • Regulatory hurdles could delay or block product launches
  • Need for future funding could lead to diluting existing shareholders
What would flip the thesis

The write-up's own warning lights — if these start happening, the case above changes.

Confidence: medium · data: USD · flags: pe, earnings_growth · Charts by TradingView Lightweight Charts™
Found this useful? The Almanac is free and ad-free - a coffee keeps it that way.Support →

Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →

This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.

Figures as of 2026-08-01. Prices may be delayed and numbers can go stale - always double-check before acting.